SAN FRANCISCO, CA / ACCESS Newswire / December 2, 2025 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in DexCom, Inc. ("DexCom") (NASDAQ:DXCM) who purchased or otherwise acquired DexCom securities between January 8, 2024 and September 17, 2025, inclusive (the "Class Period") to contact us immediately regarding the pending securities class action against DexCom. The deadline to apply to be lead plaintiff is December 26, 2025.
Class Period: January 8, 2024 – September 17, 2025
Lead Plaintiff Motion Deadline: December 26, 2025
Case information: https://lieffcabraser.com/securities/dexcom/
Contact us: Email or text investorinfo@lchb.com or call 1-800-541-7358
DexCom, incorporated in Delaware and headquartered in San Diego, California, designs, manufactures, and markets continuous glucose monitoring (CGM) systems to help individuals with types 1 and 2 diabetes monitor and control their blood sugar levels. The Company’s two key CGM products are the G6 and the G7, which DexCom launched in 2018 and in 2023, respectively.
The action alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (a) DexCom made material design changes to the G6 and G7 without FDA approval that adulterated a sensor component and which compromised the accuracy of its blood glucose reading; (b) the G7 device had significant issues with app connectivity, causing inaccurate readings and delayed alerts, and (c) as a result of these issues, the G7 exposed unsuspecting patients to significant risk of injury or death.
On July 25, 2024, after market close, DexCom announced disappointing Q2 2024 fiscal results that missed analysts’ revenue expectations and it also lowered its full year revenue guidance from $4.2 billion to $4.35 billion to $4.00 billion to $4.05 billion. The Company cited increased rebate claims and sales team reorganization as an explanation for its underperformance. On this news, the price of DexCom common stock declined $43.85 per share, or 40.66%, from a closing price of $107.85 per share on July 25, 2024, to close at $64.00 per share on July 26, 2024, on extremely heavy trading volume. A former DexCom software engineer who worked on the G7 "quality team" during the Class Period alleged that the Company’s Q2 2024 disappointing quarterly performance and reduced 2024 revenue guidance were actually due to rampant signal loss and data reception issues within the G7, which led to many complaints and a refusal from consumers to upgrade to the G7 from the G6.
On March 7, 2025, after market close, DexCom revealed that it had received a Warning Letter from the FDA on March 4, 2025 "following inspections of DexCom’s facilities in San Diego, California and Mesa, Arizona." According to DexCom, the FDA inspectors "observed non-conformities in manufacturing processes and quality management system" but assured investors that it would "not restrict the Company’s ability to produce, market, manufacture or distribute products, require recall of any products, nor restrict the Company’s ability to seek FDA 510(k) clearance of new products." On this news, the price of DexCom common stock declined another $7.12 per share, or 9.15%, from a closing price of $77.84 per share on March 7, 2025, to close at $70.72 per share on March 10, 2025, on heavy trading volume.
On March 25, 2025, the FDA published the Warning Letter that revealed that DexCom had "adulterated" its G6 and G7 products because DexCom replaced a "component used in the resistance layer" with a less accurate component without regulatory approval. The letter warned that this change resulted in "larger inaccuracies" than the prior material in measuring blood glucose, which could pose significant consumer health risks. On this news, the price of DexCom common stock declined $3.19 per share, or 4.24%, over the next two trading days, from a closing price of $75.32 per share on March 24, 2025, to close at $72.13 per share on March 26, 2025.
On September 8, 2025, equity research firm Oppenheimer downgraded its rating of DexCom to "perform" from "outperform" and removed its $102.00 price target on DexCom’s stock, citing patient and consumer concern with the G7’s inaccuracy, failed sensor insertions, abrupt stoppages, and other performance issues due to the G7’s quality and performance issues. On this news, the price of DexCom common stock fell $2.51 per share, or 3.12%, from a closing price of $80.51 per share on September 5, 2025, to close at $78.00 per share on September 8, 2025, on elevated trading volume.
On September 18, 2025, Hunterbrook, a publisher of investigative and global reporting, published a report based on witness accounts and records it obtained from the FDA through FOIA requests showing far greater injuries–and several deaths–caused by the adulterated G6 and G7 devices than DexCom had previously disclosed. On this news, the price of DexCom common stock fell $8.99 per share, or 11.76% over the next two trading days, from a closing price of $76.44 per share on September 17, 2025, to close at $67.45 per share on September 19, 2025, on extremely heavy trading volume.
These disclosures contributed to a total $12.4 billion loss in DexCom’s market capitalization. DexCom insiders sold $8.79 million of their DexCom shares while the stock was artificially inflated by Defendants’ material misstatements and omissions, and before the public was made aware of these disclosures.
About Lieff Cabraser
Lieff Cabraser Heimann & Bernstein, LLP, with over 125 attorneys in offices in San Francisco, New York, Nashville, and Munich, Germany, is an internationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility. Repeatedly recognized as a "Plaintiffs’ Powerhouse" by Law360, Lieff Cabraser has litigated some of the most important civil cases in the United States, and has assisted clients in recovering over $129 billion in verdicts and settlements. For over 50 years, Lieff Cabraser has remained committed to ensuring access to justice for all.
Source/Contact
Sharon Lee
Lieff Cabraser Heimann & Bernstein, LLP
415 956-1000
slee@lchb.com
SOURCE: Lieff Cabraser Heimann & Bernstein
View the original press release on ACCESS Newswire
COMTEX_470741508/2457/2025-12-02T07:55:09